Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 7/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | HTR7 | P34969 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613867 | 0.84 | MAPT (0.82) | MAPTHTR7LMNAKMT2AMEN1 | |
| SCHEMBL2743800 | 0.84 | ABCB1 (0.78) | ABCB1MAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL12577217 | 0.83 | MAPT (1.00) | MAPTHTR7LMNAKMT2AMEN1 | |
| SCHEMBL12575381 | 0.83 | MAPT (1.00) | MAPTHTR7LMNAKMT2AMEN1 | |
| SCHEMBL9815965 | 0.82 | HTR7 (0.76) | ABCB1MAPTHTR7LMNAKMT2A | |
| SCHEMBL25097473 | 0.82 | MAPT (0.79) | ABCB1MAPTSMN1; SMN2HTR7LMNA | |
| SCHEMBL8002897 | 0.82 | MAPT (0.79) | ABCB1MAPTSMN1; SMN2HTR7LMNA | |
| SCHEMBL8009539 | 0.82 | MAPT (0.79) | ABCB1MAPTSMN1; SMN2HTR7LMNA | |
| SCHEMBL12577234 | 0.81 | MAPT (0.81) | ABCB1MAPTSMN1; SMN2HTR7LMNA | |
| SCHEMBL25192668 | 0.81 | HTR7 (0.70) | ABCB1MAPTSMN1; SMN2HTR7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | ABCB1 264/4885MAPT 434/4885SMN1; SMN2 341/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | ABCB1 264/4885MAPT 434/4885SMN1; SMN2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.